Innovating Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Learn more Latest Company Investor presentation

Clinical Studies

We are currently conducting six international clinical research studies.

Read more

Our Pipeline

Nolasiban

(OBE001)
Oral oxytocin
receptor antagonist

Next milestones

  • EU Phase 3 IMPLANT 4 Primary endpoint data Q4 2019
  • EU MAA filing planned late 2019
  •  US Phase 3 IMPLANT 3 Initiation Q4 2019 / Q1 2020

Commercial rights

  • Exclusive Worldwide
Learn more

Linzagolix

(OBE2109)
Oral GnRH
receptor antagonist

Next milestones

Uterine Fibroids

  • Phase 3 PRIMROSE 2&1, 24-week Primary endpoint data Q4 2019 / H1 2020
  • NDA targeted end of 2020

Endometriosis

  • Phase 2b EDELWEISS 1, 76-week Follow-up completion H2 2019
  • Phase 3 EDELWEISS 2&3 enrolment Q3 2019

Commercial rights

  • Exclusive Worldwide (ex-Asia)
Learn more

OBE022

Oral and selective
prostaglandin F2
alpha receptor antagonist

Next milestones

  • EU Phase 2a PROLONG Interim Efficacy Q4 2019

Commercial rights

  • Exclusive Worldwide
Learn more

ObsEva announces new composition of its Executive Committee

September 11, 2019

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Learn more

ObsEva in the media

Learn more

Other ObsEva press releases

Learn more
 

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics? Explore our available vacancies below.

Our Vacancies